Cardiff Oncology (CRDF)
(Delayed Data from NSDQ)
$4.07 USD
+0.08 (2.01%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.20 +0.13 (3.19%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
CRDF 4.07 +0.08(2.01%)
Will CRDF be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CRDF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRDF
Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
CRDF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going
Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?
What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now?
Other News for CRDF
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
Cardiff Oncology Reveals Latest Cancer Research at AACR
Cardiff presents data underscoring 'significant potential' of onvansertib